Executive Leadership

Deniz Kural, Ph.D.
Co-Founder and Executive Chairman of the Board of Directors

As Executive Chairman of the Board of Directors, Deniz leads high-level strategy for Seven Bridges.

Brandi Davis-Dusenbery, Ph.D.
Chief Executive Officer

As CEO, Brandi focuses on delivering continued product innovation and driving Seven Bridges’ global growth.

James Sietstra

As President of Seven Bridges, James leads the company’s business growth and development and serves as a member of the Board of Directors.

Igor Bogicevic
Co-Founder and Chief Technology Officer

As Chief Technology Officer at Seven Bridges, Igor oversees the development and deployment of our robust and scalable computational infrastructure.

Michael Hultner, Ph.D.
Chief Strategy Officer

As Chief Strategy Officer, Michael oversees the strategic direction, expansion, and operation of Seven Bridges’ commercial teams, serving both government and pharmaceutical clients.

Milan Mitrovic
Chief Product Officer

As Chief Product Officer, Milan oversees the entire Seven Bridges product roadmap.

Bruce Press
Executive Vice President of Commercial Operations

As Executive Vice President of Commercial Operations, Bruce focuses on building strategic relationships with biotech and pharmaceutical enterprises.


Tom Daschle
Former U.S. Senate Majority Leader
Founder and CEO of The Daschle Group

Senator Daschle is the Founder and CEO of The Daschle Group, A Public Policy Advisory of Baker Donelson.

Kai-Fu Lee, Ph.D.
CEO, Sinovation Ventures

Kai-Fu Lee is CEO of Sinovation Ventures, an incubation, venture capital, and software company with offices in Beijing, Shanghai, and Shenzhen China.

James Knight, Ph.D.
Director of Bioinformatics and Research Scientist
Yale University

James Knight’s research focuses on the alignment, variant calling and annotation of exome sequencing and whole genome sequencing datasets.

Jan Korbel, Ph.D.
Principal Investigator and Senior Scientist
European Molecular Biology Laboratory (EMBL)

Jan Korbel is particularly interested in understanding determinants of genomic DNA rearrangement formation and selection, for example in the context of enhancer hijacking or catastrophic DNA alterations.

Charles Lee, Ph.D.
Scientific Director and Professor
The Jackson Laboratory (JAX) for Genomic Medicine

Charles Lee is a distinguished biomedical scientist who first discovered widespread structural variation in the human genome in 2004, in the form of copy number variation (CNV).

Gholson Lyon, Ph.D., M.D.
Research Scientist
Cold Spring Harbor Laboratory and the Utah Foundation for Biomedical Research.

Gholson Lyon’s research focuses on human genetics and genomic medicine, with an emphasis on diseases with severe neuropsychiatric manifestations, including Tourette syndrome, attention-deficit hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), autism and schizophrenia.

Gokhan Hotamisligil, Ph.D., M.D.
James S. Simmons Professor of Genetics & Metabolism, Chair, Department of Genetics & Complex Diseases, Director, Sabri Ülker Center for Metabolic Research
Assoc. Member, Harvard-MIT Broad Institute, Harvard Stem Cell Institute, Joslin Diabetes Center.

Gokhan Hotamisligil’s research efforts focus on the molecular and genetic basis of common and complex diseases, particularly obesity, diabetes, and heart disease.

Heng Li, Ph.D.
Research Scientist, Broad Institute

Heng Li’s research focuses on population genetics and phylogenetics. He is the principal developer of several bioinformatics projects, including SAMtools, BWA, MAQ, TreeSoft and TreeFam.